Cargando…

Multimerization of Ebola GPΔmucin on protein nanoparticle vaccines has minimal effect on elicitation of neutralizing antibodies

Ebola virus (EBOV), a member of the Filoviridae family of viruses and a causative agent of Ebola Virus Disease (EVD), is a highly pathogenic virus that has caused over twenty outbreaks in Central and West Africa since its formal discovery in 1976. The only FDA-licensed vaccine against Ebola virus, r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powell, Abigail E., Xu, Duo, Roth, Gillie A., Zhang, Kaiming, Chiu, Wah, Appel, Eric A., Kim, Peter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449635/ https://www.ncbi.nlm.nih.gov/pubmed/36091016 http://dx.doi.org/10.3389/fimmu.2022.942897

Ejemplares similares

Hydrogel‐Based Slow Release of a Receptor‐Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS‐CoV‐2
por: Gale, Emily C., et al.
Publicado: (2021)

Eliciting neutralizing antibodies with gp120 outer domain
por: Qin, Y, et al.
Publicado: (2012)

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice
por: Powell, Abigail E., et al.
Publicado: (2020)

A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
por: Powell, Abigail E., et al.
Publicado: (2021)

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
por: Chevillard, Christopher, et al.
Publicado: (2022)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Structures of Ebola Virus GP and sGP in Complex with Therapeutic Antibodies
por: Pallesen, Jesper, et al.
Publicado: (2016)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
por: Krebs, Shelly J., et al.
Publicado: (2014)

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
por: Qiu, Xiangguo, et al.
Publicado: (2009)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Correction: Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
Publicado: (2015)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

The third RNA recognition motif of Drosophila ELAV protein has a role in multimerization
por: Toba, Gakuta, et al.
Publicado: (2008)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
por: Ching, LK, et al.
Publicado: (2009)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease
por: Luczkowiak, Joanna, et al.
Publicado: (2018)

Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection
por: Qiu, Xiangguo, et al.
Publicado: (2012)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

The role of the charged residues of the GP2 helical regions in Ebola entry
por: Jiang, Haiqing, et al.
Publicado: (2009)

Ebola sGP—The first viral glycoprotein shown to be C-mannosylated
por: Falzarano, Darryl, et al.
Publicado: (2007)

Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity
por: Agnolon, Valentina, et al.
Publicado: (2020)

HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life
por: Yates, N L, et al.
Publicado: (2013)

Multimerization rules for G-quadruplexes
por: Kolesnikova, Sofia, et al.
Publicado: (2017)

Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model
por: Lee, Ha-Na, et al.
Publicado: (2021)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate
por: Narayan, Kristin M., et al.
Publicado: (2013)

Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120
por: Jiang, Pengfei, et al.
Publicado: (2006)

Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies
por: Bornholdt, Zachary A., et al.
Publicado: (2016)

Comprehensive Functional Analysis of N-Linked Glycans on Ebola Virus GP1
por: Lennemann, Nicholas J., et al.
Publicado: (2014)

Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability
por: Escudero-Pérez, Beatriz, et al.
Publicado: (2014)

Design of universal Ebola virus vaccine candidates via immunofocusing
por: Xu, Duo, et al.
Publicado: (2023)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus
por: Roman-Sosa, Gleyder, et al.
Publicado: (2022)

Vaccine with bacterium‐like particles displaying HIV‐1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques
por: Wang, Huaiyu, et al.
Publicado: (2022)

Myomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice
por: Kuchař, Milan, et al.
Publicado: (2021)

Injectable supramolecular polymer–nanoparticle hydrogels enhance human mesenchymal stem cell delivery
por: Grosskopf, Abigail K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pd02kdqf6jm33cre3lp10v2r3n